Charles River Laboratories Intl. Inc vs Star Bulk Carriers Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Star Bulk Carriers Corp trades at $29.7 (market cap $3.54B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 4× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 6.17% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Star Bulk Carriers Corp for 24 Days on average.
| CRL | SBLK | |
|---|---|---|
Market Cap | $14.23B | $3.54B |
Volume | 1,176,885 | 1,437,622 |
Sector | Health | Industrials |
52-Week High | $310.77 | $32.49 |
52-Week Low | $149.93 | $16.79 |
Typical Hold Time | 33 Days | 24 Days |
Enterprise Value | $17.06B | $4.22B |
Dividend Yield | — | 6.17% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
Star Bulk Carriers (SBLK) trades at $30.47, up 2.63% today, with a bullish technical signal from moving averages and consistent earnings beats in recent quarters. The company reported strong Q2 2026 EPS of $1.21, exceeding expectations, and maintains a 100% free cash flow distribution policy, highlighted by a $0.90 dividend for H2 2026. Valuation metrics show a P/E of 11.95 and EV/EBITDA of 8.34, indicating reasonable pricing relative to earnings.
The outlook remains positive due to robust earnings growth, shareholder returns, and insider buying, but risks include shipping market volatility and reliance on global trade cycles. Analyst consensus is bullish with 14 buy ratings, supporting potential upside if operational momentum continues.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →